Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients With Relapsed Non Small Cell Lung Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-0717
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Early Breast Cancer: Results of a Pre-Operative Study

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2015English

A Phase I Trial of Temsirolimus and Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer

Chemotherapy
MedicineDrug DiscoveryInfectious DiseasesOncologyPharmacology
2016English

Erlotinib Treatment in Pretreated Patients With Non-Small Cell Lung Cancer: A Phase II Study

Oncology Letters
Cancer ResearchOncology
2010English

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2009English

Mammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging

Annals of the American Thoracic Society
PulmonaryRespiratory Medicine
2016English

P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Outcome Analysis of Phase I Trial Patients With Metastatic KRAS and/or TP53 Mutant Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy